Pegasystems (PEGA) Stock Can Q3 Results Revive Confidence In ACV Growth?

Simply Wall St · 2d ago

Pegasystems stock slipped about 3% to US$35.18 on Thursday, even after posting another profitable quarter for Q3 2026. Traders focused on the softer quarterly rhythm, yet the real story sits in the recurring engine underneath. Annual contract value, the key gauge for a software subscription business, reached US$1.66b with Pega Cloud accounting for the majority of that base. When viewed over a multi year horizon, that subscription footprint and the current P/E of 19.6 present a very different debate than a single red day on the screen.

Love the recurring subscription engine at Pegasystems but uneasy about paying up for a tech stock after a soft quarter? You can compare that setup to a curated group of software and IT names on our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): US$393.4m vs. US$381.4m (up about 3%)
  • Net Income, Excl. Extra Items (Q3 2026 vs. Q3 2025): US$14.1m vs. US$43.4m (down about 68%)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$0.09 vs. US$0.25 (declined about 66%)
  • Annual Contract Value (ACV, Q3 2026 vs. Q3 2025): US$1.66b vs. prior year level (up 7% year on year, constant currency)

Ask Charlie what Pegasystems’ AI “Blueprint” really changes for clients.

NasdaqGS:PEGA Trailing 12-Month Earnings & Revenue History as at Oct 2026
NasdaqGS:PEGA Trailing 12-Month Earnings & Revenue History as at Oct 2026

Pegasystems’ AI Workflow Story Meets Mixed Execution

The bullish view depends on Pegasystems turning AI workflows into a higher quality contract engine and faster subscription gains.

"The main thing that has to go right is that enterprises continue to adopt Pegasystems as a governed workflow and AI orchestration layer. This would turn tools like Infinity 26, Blueprint, and public sector offerings into larger, higher quality pipelines and signed ACV."

Q3 shows partial progress. ACV reached US$1.66b with 7% year on year growth and Pega Cloud at 59% of that base, plus the strongest net new ACV quarter of 2026. That supports the adoption story. Management still expects full year ACV growth at or below about 10%, which suggests that conversion of those pipelines into signed deals is not yet matching the bullish pace.

One Narrative disagrees with today's price. → See where this Narrative says Pegasystems should trade.

Pegasystems Bear Case: Execution Wobbles Still Visible

The cautious view argues Pegasystems will keep falling behind faster growing workflow rivals because sales execution and deal quality fail to keep up.

"The shift from an account manager model to a hunter focused go to market approach is intended to expand Pegasystems’ reach. However, management’s own admission of complacency on pipeline building and slower execution around this pivot suggests that any sales productivity benefits could arrive later than anticipated, putting pressure on subscription revenue growth and net margins if selling costs stay elevated."

Q3 results largely support that concern. Revenue of US$393.4m missed consensus by a wide margin. ACV growth of 7% and full year commentary capped at about 10% fall short of the faster, cleaner acceleration that would indicate this go to market reset is already working. Net income excluding extra items dropped sharply, which keeps the pressure narrative on margins alive.

Hunt For Mispriced Cash Generators

Pegasystems shows how a headline quarter can leave investors debating the underlying engine. The real opportunity could sit in stocks that look misaligned with their business progress before the market closes the gap.

  • Company 1 - 29% below our estimate - turns record engineering wins in complex regulated programs into higher margin manufacturing workloads.
  • Company 2 - 40% below our estimate - channels heavier spending on AI, digital infrastructure and payments into scalable fee-based banking services.
  • Company 3 - 26% below our estimate - sells injectable treatments for diabetes and weight loss that major healthcare payors reimburse across long-term care plans.

Three companies from the same screener. Open the full list of 33 companies trading below our fair value estimates →